Cenobamate, a new epilepsy drug was established as safe and effective with reduced seizure frequency and higher seizure-freedom rate. A post hoc analyses from an open-label study, including 240 adult participants found 73.8% retention rate and 25.8% seizure freedom for >12 months. 33.9% of those who continued taking cenobamate were seizure free for about 23.5 months and 24.8% displayed discontinuation of concomitant anti-seizure medications. An open label study was performed earlier on 1347 patients to assess the safety and pharmacokinetics. Results suggested that cenobamate, when administered with “slow and low titration”, did not cause any case of drug reaction with eosinophilia and systemic symptoms (DRESS). Cenobamate has been approved by the US FDA for the treatment of uncontrolled partial-onset seizures in adults and it reduces seizures by either inhibiting the sodium current or by affecting the GABA-A channel.
